Today: 9 June 2026
City Developments (CDL) share price ticks up near 52-week high as brokers flag Newport catalyst
21 January 2026
2 mins read

City Developments (CDL) share price ticks up near 52-week high as brokers flag Newport catalyst

Singapore, Jan 21, 2026, 15:19 SGT — Regular session

  • Shares of City Developments rose 0.7% in afternoon trading, closing in on a 52-week high
  • RHB and DBS highlighted asset sales and the launch of Newport Residences as potential near-term catalysts
  • Investors are focused on bookings for Jan 31 and the FY2025 results scheduled for Feb 27

Shares of City Developments Limited nudged up Wednesday, lingering close to a 52-week peak after broker notes flagged a luxury launch and asset sales as potential catalysts soon. The stock rose 0.66% to S$9.16 by 3:08 p.m., trading in a range between S$9.03 and S$9.22 during the session, per SGX data gathered by SGinvestors.io.

Timing is crucial for the sector. Singapore property stocks are once again reacting to interest rate shifts, as falling local borrowing costs boost affordability and spark greater risk appetite for developers carrying leverage on their balance sheets.

Valuation is another key factor. Broker reports from the last two days have focused on revalued net asset value, or RNAV — a metric analysts rely on to gauge what a developer’s assets would fetch when adjusted to current market levels. The idea is straightforward: sell units, recycle capital, and narrow the discount.

City Developments climbed, despite the FTSE Straits Times Index slipping roughly 0.4% in afternoon trading.

Vijay Natarajan, analyst at RHB Bank Singapore, flagged growing momentum in Singapore real estate stocks, pointing to lower interest rates and pent-up demand. He maintained an overweight rating on the sector, highlighting City Developments as a top pick. Natarajan noted the stock is “still trading at a hefty more than 40% discount” to his RNAV estimate. The Edge Singapore

Natarajan highlighted City Developments’ quicker asset sales, totaling around S$2 billion last year, as a strategy to tackle worries about debt and boost returns for shareholders.

On the macro front, he pointed to more affordable mortgage deals, with banks now offering fixed-rate home loans in the 1.55% to 1.6% range following a sharp drop in Singapore’s benchmark SORA (Singapore Overnight Rate Average) last year. That report also estimated the 2026 launch pipeline at roughly 12,000 new private units across 24 projects, including executive condominiums.

DBS Group Research flagged the launch of Newport Residences as a potential boost for City Developments’ shares. They forecast margins topping 20% and a 3% to 4% gain in RNAV. The bank expects pricing just above S$3,000 per square foot (psf), adding that “a 30–40% sell-through rate at launch would be very healthy.” DBS stuck with its buy rating and S$11.80 target. The Edge Singapore

City Developments announced that sales bookings for the 246-unit Newport Residences will open on Jan 31, following previews that started on Jan 16. Prices kick off at S$1.298 million for a one-bedroom unit. Group CEO Sherman Kwek said “the time is right” to launch the project, citing strong demand in recent prime-area developments. CDL

The upside isn’t straightforward. Demand for prime-city units can shift quickly with changes in policy and interest rates. Brokers also point to the 60% additional buyer’s stamp duty (ABSD) — a property purchase tax — as a continuing obstacle for foreign buyers targeting the high-end market.

Attention will turn to take-up as Newport bookings open on Jan 31. City Developments plans to unveil unaudited FY2025 results before the Feb 27 session, with a briefing set for that morning, according to an SGX filing.

Stock Market Today

  • Semiconductor Stock Poised to Surpass Micron Technology by 2028
    June 9, 2026, 10:18 AM EDT. Micron Technology has surged nearly 800% recently, driven by high demand and pricing power in memory chips, pushing its market cap past $1 trillion. However, analysts predict supply constraints easing by 2028 could cause earnings to peak and decline, potentially halving share value to around $517.50. Meanwhile, a major semiconductor competitor valued around $650 billion is expanding production, potentially surpassing Micron's value by 2028. The industry faces cyclical dynamics as new manufacturing capacity comes online globally, impacting pricing and earnings. Investors are watching these shifts closely for long-term positioning amid evolving chip supply and demand.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Dow Jones today: Dow drops 870 points on Trump Greenland tariff threat as volatility jumps
Previous Story

Dow Jones today: Dow drops 870 points on Trump Greenland tariff threat as volatility jumps

BAE Systems share price: fresh buyback filing hits tape before London open
Next Story

BAE Systems share price: fresh buyback filing hits tape before London open

Go toTop